NCT05741853 · RECRUITING

Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia

This trial is testing two speech-language therapy approaches — script training and word-finding practice — in bilingual people who have primary progressive aphasia, a brain disease that attacks language first. Researchers want to know whether tailoring therapy to both of a person's languages works better than standard approaches. This is a Phase NA efficacy trial, meaning it is evaluating how well the intervention works in a specific population, not yet a large-scale proven treatment.

You may qualify if

  • Meets diagnostic criteria for Primary Progressive Aphasia (PPA; Gorno-Tempini et al., 2011)
  • Bilingual in Spanish and Catalan or bilingual in Spanish and English
  • Different proficiency levels across languages are expected, any prior experience in both languages is acceptable
  • Intervention study: Score of 15 or higher on the Mini-Mental State Examination
  • Note that this project will also recruit individuals to participate in assessment only, for these individuals the following inclusion criteria applies: Score of 10 or higher on the Mini-Mental State Examination

You're excluded if

  • Other central nervous system or medical diagnosis that can cause symptoms
  • Other psychiatric diagnosis that can cause symptoms
  • Significant, uncorrected visual or hearing impairment that would interfere with participation
  • Prominent initial non-speech-language impairments (cognitive, behavioral, motoric)
  • Intervention Study: Score of less than 15 on the Mini-Mental State Examination
  • Note that this project will also recruit individuals to participate in assessment only, for these individuals the following inclusion criteria applies: Score of less than 10 on the Mini-Mental State Examination

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2025-11-12

View full record on ClinicalTrials.gov

All APOE4 clinical trials